ReviewJournal of the American College of Cardiology2009
End points for clinical trials in acute heart failure syndromes.
Review in Journal of the American College of Cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Temporal Trends and Factors Associated With the Inclusion of Patient-Reported Outcomes in Heart Failure Randomized Controlled Trials: A Systematic Review.Journal of the American Heart Association · 2021Pooled it
- Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials.Journal of cardiac failure · 2021Trial
- Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure.The American journal of cardiology · 2010Trial
- Istaroxime in Acute Heart Failure and Early Cardiogenic Shock: A Calcium-Cycling Approach to Inotropic Therapy.International journal of molecular sciences · 2026Review
- Statistical modeling of days alive out-of-hospital: An illustration using the SSU trial.Journal of clinical and translational science · 2026Article
- Use of Digital Health Technology in Heart Failure and Diabetes: a Scoping Review.Journal of cardiovascular translational research · 2023Article
- Association of colchicine use for acute gout with clinical outcomes in acute decompensated heart failure.Clinical cardiology · 2022Article
- Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.Circulation. Heart failure · 2022Review
- Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.Circulation research · 2021Review
- Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey.Clinical research in cardiology : official journal of the German Cardiac Society · 2019Article
- Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications.ESC heart failure · 2019Article
- Article
- Death: The Simple Clinical Trial Endpoint.Studies in health technology and informatics · 2019Article
- Drugs' development in acute heart failure: what went wrong?Heart failure reviews · 2018Review
- An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.Statistical methods in medical research · 2018Article
- Article
- Acute Heart Failure: Definition, Classification and Epidemiology.Current heart failure reports · 2017Review
- End points in heart failure-are we doing it right?European journal of clinical pharmacology · 2017Review
- Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure.Journal of intensive care · 2016Review
- The Impact of Worsening Heart Failure in the United States.Heart failure clinics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acute heart failure syndromes (AHFS) remain a major cause of morbidity and mortality, in part because the development of new therapies for these disorders has been marked by frequent failure and little success. The heterogeneity of current approaches to AHFS drug development, particularly with regard to end points, remains a major potential barrier to progress in the field. End points involving hemodynamic status, biomarkers, symptoms, hospital stay, end organ function, and mortality have all been employed either alone or in combination in recent randomized clinical trials in AHFS. In this review, we will discuss the various end point domains from both a clinical and a statistical perspective, summarize the wide variety of end points used in completed and ongoing AHFS studies, and suggest steps for greater standardization of end points across AHFS trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.